225 related articles for article (PubMed ID: 26940667)
1. Disease-modifying anti-rheumatic drug use in pregnant women with rheumatic diseases: a systematic review of the risk of congenital malformations.
Baldwin C; Avina-Zubieta A; Rai SK; Carruthers E; De Vera MA
Clin Exp Rheumatol; 2016; 34(2):172-83. PubMed ID: 26940667
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
Clowse MEB; Scheuerle AE; Chambers C; Afzali A; Kimball AB; Cush JJ; Cooney M; Shaughnessy L; Vanderkelen M; Förger F
Arthritis Rheumatol; 2018 Sep; 70(9):1399-1407. PubMed ID: 29623679
[TBL] [Abstract][Full Text] [Related]
3. Biologic therapy use and pregnancy outcomes in women with immune-mediated inflammatory rheumatic diseases.
Brites L; Madeira N; Rodrigues J; Marona J; Martins N; Águeda A; Freitas R; Neto A; Capela S; Sequeira G; Ganhão S; Duarte C; Santiago M; Santos MJ
Acta Reumatol Port; 2019; 44(4):266-272. PubMed ID: 32008032
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers.
Viktil KK; Engeland A; Furu K
Scand J Rheumatol; 2012 May; 41(3):196-201. PubMed ID: 22401133
[TBL] [Abstract][Full Text] [Related]
5. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence.
Mouyis M; Flint JD; Giles IP
Semin Arthritis Rheum; 2019 Apr; 48(5):911-920. PubMed ID: 30220537
[TBL] [Abstract][Full Text] [Related]
6. No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs.
Wallenius M; Lie E; Daltveit AK; Salvesen KÅ; Skomsvoll JF; Kalstad S; Lexberg ÅS; Mikkelsen K; Kvien TK; Østensen M
Arthritis Rheumatol; 2015 Jan; 67(1):296-301. PubMed ID: 25418443
[TBL] [Abstract][Full Text] [Related]
7. Hydroxychloroquine early in pregnancy and risk of birth defects.
Huybrechts KF; Bateman BT; Zhu Y; Straub L; Mogun H; Kim SC; Desai RJ; Hernandez-Diaz S
Am J Obstet Gynecol; 2021 Mar; 224(3):290.e1-290.e22. PubMed ID: 32961123
[TBL] [Abstract][Full Text] [Related]
8. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation.
Levy RA; de Jesús GR; de Jesús NR; Klumb EM
Autoimmun Rev; 2016 Oct; 15(10):955-63. PubMed ID: 27490204
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy and rheumatic diseases.
Malviya AN
J Assoc Physicians India; 1994 Feb; 42(2):178. PubMed ID: 7860501
[No Abstract] [Full Text] [Related]
10. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids.
Flint J; Panchal S; Hurrell A; van de Venne M; Gayed M; Schreiber K; Arthanari S; Cunningham J; Flanders L; Moore L; Crossley A; Purushotham N; Desai A; Piper M; Nisar M; Khamashta M; Williams D; Gordon C; Giles I;
Rheumatology (Oxford); 2016 Sep; 55(9):1693-7. PubMed ID: 26750124
[No Abstract] [Full Text] [Related]
11. The use of biologics in pregnant patients with rheumatic disease.
Østensen M
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):661-669. PubMed ID: 28326845
[TBL] [Abstract][Full Text] [Related]
12. Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study.
Andreoli L; Gerardi MC; Gerosa M; Rozza D; Crisafulli F; Erra R; Lini D; Trespidi L; Padovan M; Ruffilli F; Serale F; Cuomo G; Raffeiner B; Semeraro P; Tani C; Chimenti MS; Conigliaro P; Hoxha A; Nalli C; Fredi M; Lazzaroni MG; Filippini M; Taglietti M; Franceschini F; Zatti S; Loardi C; Orabona R; Ramazzotto F; Zanardini C; Fontana G; Gozzoli G; Barison C; Bizioli P; Caporali RF; Carrea G; Ossola MW; Maranini B; Silvagni E; Govoni M; Morano D; Verteramo R; Doria A; Del Ross T; Favaro M; Calligaro A; Tonello M; Larosa M; Zen M; Zambon A; Mosca M; Zucchi D; Elefante E; Gori S; Iannone F; Anelli MG; Lavista M; Abbruzzese A; Fasano CG; D'Angelo S; Cutro MS; Picerno V; Carbone T; Padula AA; Rovere-Querini P; Canti V; De Lorenzo R; Cavallo L; Ramoni V; Montecucco C; Codullo V; Milanesi A; Pazzola G; Comitini G; Marvisi C; Salvarani C; Epis OM; Benedetti S; Di Raimondo G; Gagliardi C; Lomater C; Crepaldi G; Bellis E; Bellisai F; Garcia Gonzalez E; Pata AP; Zerbinati M; Urban ML; Mattioli I; Iuliano A; Sebastiani G; Brucato AL; Bizzi E; Cutolo M; Santo L; Tonetta S; Landolfi G; Carrara G; Bortoluzzi A; Scirè CA; Tincani A;
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38663885
[TBL] [Abstract][Full Text] [Related]
13. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation.
Ostensen M
Am J Reprod Immunol; 1992; 28(3-4):148-52. PubMed ID: 1285866
[TBL] [Abstract][Full Text] [Related]
14. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.
Götestam Skorpen C; Hoeltzenbein M; Tincani A; Fischer-Betz R; Elefant E; Chambers C; da Silva J; Nelson-Piercy C; Cetin I; Costedoat-Chalumeau N; Dolhain R; Förger F; Khamashta M; Ruiz-Irastorza G; Zink A; Vencovsky J; Cutolo M; Caeyers N; Zumbühl C; Østensen M
Ann Rheum Dis; 2016 May; 75(5):795-810. PubMed ID: 26888948
[TBL] [Abstract][Full Text] [Related]
15. Use of colchicine in pregnancy: a systematic review and meta-analysis.
Indraratna PL; Virk S; Gurram D; Day RO
Rheumatology (Oxford); 2018 Feb; 57(2):382-387. PubMed ID: 29029311
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
Lee YH; Bae SC; Song GG
Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future.
Vroom F; de Walle HE; van de Laar MA; Brouwers JR; de Jong-van den Berg LT
Drug Saf; 2006; 29(10):845-63. PubMed ID: 16970509
[TBL] [Abstract][Full Text] [Related]
18. Prescribing of sulfasalazine, azathioprine and methotrexate round pregnancy--a descriptive study.
Vroom F; van Roon EN; van den Berg PB; Brouwers JR; de Jong-van den Berg LT
Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):52-61. PubMed ID: 17948319
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy.
Nguyen H; Ahmed K; Luo W; Flint J; Giles I
Semin Arthritis Rheum; 2021 Dec; 51(6):1205-1217. PubMed ID: 34689007
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study.
Weber-Schoendorfer C; Chambers C; Wacker E; Beghin D; Bernard N; ; Shechtman S; Johnson D; Cuppers-Maarschalkerweerd B; Pistelli A; Clementi M; Winterfeld U; Eleftheriou G; Pupco A; Kao K; Malm H; Elefant E; Koren G; Vial T; Ornoy A; Meister R; Schaefer C
Arthritis Rheumatol; 2014 May; 66(5):1101-10. PubMed ID: 24470106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
